Please ensure Javascript is enabled for purposes of website accessibility

AstraZeneca Might Receive Emergency Use Authorization for Its Coronavirus Vaccine

By Taylor Carmichael – Aug 24, 2020 at 2:29PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One report suggests that the U.K.-based company might win the coronavirus vaccine race in the U.S.

The Financial Times reported on Sunday that the U.S. Food and Drug Administration (FDA) might grant an emergency use authorization (EUA) in October to a vaccine for COVID-19 being developed by AstraZeneca (AZN 0.59%) and licensed from Oxford University. The vaccine, AZD1222, is currently in a phase 3 clinical trial that is now trying to enroll 30,000 people around the world in order to assess the safety and efficacy of the vaccine candidate.

With the COVID-19 pandemic having so far killed over 800,000 people worldwide -- and with reports that President Trump is trying to fast-track a vaccine before this November's U.S. election -- there is pressure on the FDA to grant approval for a vaccine as soon as possible. According to the Financial Times report, one plan being considered is for AstraZeneca to submit an EUA based on part of the phase 3 study being conducted in the U.K., involving a subset of 10,000 people.

Multiple vials labeled as coronavirus vaccines

Image source: Getty Images.

According to FDA guidance, emergency use authorization might happen after "a determination by the FDA that the known and potential benefits of a product, when used to diagnose, prevent, or treat serious or life-threatening diseases, outweigh the known and potential risks of the product." None of the phase 1 vaccine trials would likely be deemed sufficient for an EUA, as they have only safety and antibody data and are not testing efficacy in people. 

While AstraZeneca's 10,000 subset of its phase 3 trial would likely be sufficient for an EUA, the company denies any talks with U.S. officials about submitting one, according to Fortune magazine. "AstraZeneca has not discussed emergency use authorization with the US government and it would be premature to speculate on that possibility," the company said in a statement on Monday.

Taylor Carmichael has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

AstraZeneca Plc Stock Quote
AstraZeneca Plc
$69.58 (0.59%) $0.41

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.